IL131298A - An ointment preparation containing FK506 or a similar compound and a process for its preparation - Google Patents

An ointment preparation containing FK506 or a similar compound and a process for its preparation

Info

Publication number
IL131298A
IL131298A IL13129898A IL13129898A IL131298A IL 131298 A IL131298 A IL 131298A IL 13129898 A IL13129898 A IL 13129898A IL 13129898 A IL13129898 A IL 13129898A IL 131298 A IL131298 A IL 131298A
Authority
IL
Israel
Prior art keywords
group
hydrogen atom
hydroxy
independently
alkyl
Prior art date
Application number
IL13129898A
Other languages
English (en)
Hebrew (he)
Other versions
IL131298A0 (en
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of IL131298A0 publication Critical patent/IL131298A0/xx
Publication of IL131298A publication Critical patent/IL131298A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
IL13129898A 1997-02-20 1998-02-18 An ointment preparation containing FK506 or a similar compound and a process for its preparation IL131298A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3617297 1997-02-20
JP25635797 1997-09-22
PCT/JP1998/000665 WO1998036747A1 (fr) 1997-02-20 1998-02-18 Composition pharmaceutique

Publications (2)

Publication Number Publication Date
IL131298A0 IL131298A0 (en) 2001-01-28
IL131298A true IL131298A (en) 2004-06-20

Family

ID=26375217

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13129898A IL131298A (en) 1997-02-20 1998-02-18 An ointment preparation containing FK506 or a similar compound and a process for its preparation

Country Status (21)

Country Link
US (1) US6387918B1 (fr)
EP (1) EP0977565B1 (fr)
JP (1) JP3396888B2 (fr)
KR (1) KR100490357B1 (fr)
CN (1) CN1178656C (fr)
AR (1) AR011846A1 (fr)
AT (1) ATE237325T1 (fr)
AU (1) AU727337B2 (fr)
BR (1) BR9807234B1 (fr)
CA (1) CA2282345C (fr)
DE (1) DE69813542T2 (fr)
DK (1) DK0977565T3 (fr)
EA (1) EA003580B1 (fr)
ES (1) ES2193515T3 (fr)
HK (1) HK1027957A1 (fr)
HU (1) HU226163B1 (fr)
IL (1) IL131298A (fr)
NO (1) NO325103B1 (fr)
PT (1) PT977565E (fr)
TW (1) TW450810B (fr)
WO (1) WO1998036747A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139210A (en) * 1998-04-27 2005-11-20 Fujisawa Pharmaceutical Co Pharmaceutical composition containing a macrolide compound
GB9817064D0 (en) * 1998-08-05 1998-10-07 Fujisawa Pharmaceutical Co New use
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
CA2467828C (fr) 2001-11-29 2011-10-04 3M Innovative Properties Company Formulations pharmaceutiques comprenant un modificateur de reponse immunitaire
AU2003272471B2 (en) 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
BRPI0413927B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
PT1663217E (pt) 2003-08-29 2010-10-18 Lifecycle Pharma As Dispersão sólida que compreende tacromílus
EP1682132A1 (fr) * 2003-09-18 2006-07-26 Macusight, Inc. Administration transsclerale
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
AU2006213673A1 (en) * 2005-02-09 2006-08-17 Santen Pharmaceutical Co., Ltd. Formulations for ocular treatment
CA2635797C (fr) 2006-02-09 2015-03-31 Macusight, Inc. Formulations stables et leurs procedes de preparation et d'utilisation
US7672006B2 (en) * 2006-02-22 2010-03-02 Xerox Corporation Multi-marking engine printing platform
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
JP2009533440A (ja) * 2006-04-10 2009-09-17 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ拮抗薬塩
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
EP2167033B1 (fr) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Forme pharmaceutique orale à administrer une fois par jour comportant du tacrolimus
CA2738831C (fr) * 2008-10-08 2016-05-24 Takata Seiyaku Co., Ltd. Preparation de tacrolimus pour applications externes
LT2575769T (lt) * 2010-02-17 2016-10-10 Veloxis Pharmaceuticals A/S Stabilizuota takrolimuzo kompozicija
WO2012011192A1 (fr) * 2010-07-23 2012-01-26 マルホ株式会社 Composition crémeuse de type huile dans l'eau contenant du tacrolimus
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
KR101890011B1 (ko) * 2011-12-07 2018-08-20 히사미쓰 세이야꾸 가부시키가이샤 첩부제
JP6084579B2 (ja) * 2012-01-25 2017-02-22 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
US20180243224A1 (en) 2015-08-19 2018-08-30 Vivus, Inc. Pharmaceutical formulations
JP6997222B2 (ja) 2017-06-23 2022-01-17 ザ プロクター アンド ギャンブル カンパニー 皮膚の外観を改善するための組成物及び方法
WO2019233722A1 (fr) 2018-06-08 2019-12-12 Almirall, S.A. Composition pharmaceutique comprenant du tacrolimus
EP3817717A1 (fr) 2018-07-03 2021-05-12 The Procter & Gamble Company Méthode de traitement d'une affection cutanée
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
EP4157206A1 (fr) 2020-06-01 2023-04-05 The Procter & Gamble Company Méthode d'amélioration de la pénétration d'un composé de vitamine b3 dans la peau
AU2022230995A1 (en) 2021-03-03 2023-09-14 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA905202B (en) * 1989-07-05 1991-04-24 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
ATE150304T1 (de) * 1990-09-04 1997-04-15 Fujisawa Pharmaceutical Co Tricyclische verbindungen enthaltende salben
CA2054983A1 (fr) * 1990-11-08 1992-05-09 Sotoo Asakura Composition suspensible et procede de fabrication
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
CN1089233C (zh) * 1994-10-26 2002-08-21 诺瓦蒂斯有限公司 药物组合物

Also Published As

Publication number Publication date
IL131298A0 (en) 2001-01-28
CN1178656C (zh) 2004-12-08
JP3396888B2 (ja) 2003-04-14
HUP0000979A1 (hu) 2000-10-28
CA2282345C (fr) 2008-10-21
EA003580B1 (ru) 2003-06-26
DE69813542D1 (de) 2003-05-22
DK0977565T3 (da) 2003-08-04
ES2193515T3 (es) 2003-11-01
WO1998036747A1 (fr) 1998-08-27
EP0977565B1 (fr) 2003-04-16
PT977565E (pt) 2004-01-30
JP2000513739A (ja) 2000-10-17
CN1252721A (zh) 2000-05-10
KR100490357B1 (ko) 2005-05-17
US6387918B1 (en) 2002-05-14
EA199900749A1 (ru) 2000-04-24
HUP0000979A3 (en) 2002-10-28
KR20000070824A (ko) 2000-11-25
HU226163B1 (en) 2008-05-28
DE69813542T2 (de) 2003-11-20
TW450810B (en) 2001-08-21
ATE237325T1 (de) 2003-05-15
AR011846A1 (es) 2000-09-13
NO994003L (no) 1999-10-19
US20020032212A1 (en) 2002-03-14
AU727337B2 (en) 2000-12-07
AU6228998A (en) 1998-09-09
CA2282345A1 (fr) 1998-08-27
BR9807234B1 (pt) 2013-11-05
NO994003D0 (no) 1999-08-19
NO325103B1 (no) 2008-02-04
HK1027957A1 (en) 2001-02-02
BR9807234A (pt) 2000-04-25
EP0977565A1 (fr) 2000-02-09

Similar Documents

Publication Publication Date Title
EP0977565B1 (fr) Composition pharmaceutique comprenant un compose tricyclique ayant une meilleure stabilite, absorbabilite et de moindre irritation
US6346537B1 (en) Medicinal composition
EP0484936B1 (fr) Suspensions à base de composés tricycliques
US6673808B1 (en) Medicinal compositions
US6316473B1 (en) Two surfactant-containing medicinal composition
US6979461B1 (en) Method for producing liposome preparation
US20040220204A1 (en) Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
AU2002302969A1 (en) Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
MXPA99007451A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HC Change of name of proprietor(s)
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees